Adra2B Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{-
| Attribute |
Value |
| Protein Name |
ADRA2B, Alpha-2B Adrenergic Receptor |
| Gene Symbol |
adra2b |
| UniProt ID |
P47820 |
| Molecular Weight |
~50-60 kDa |
| Subcellular Localization |
Cell membrane |
| Protein Family |
Class A GPCR, α2-adrenergic family |
| Ligand |
Norepinephrine, epinephrine, clonidine |
| Signal Transduction |
Gi/o protein, ↓cAMP |
-}}
The Alpha-2B Adrenergic Receptor (ADRA2B) is an inhibitory G protein-coupled receptor that regulates sympathetic tone, cardiovascular function, and central nervous system activity. It belongs to the α2-adrenergic receptor subfamily (ADRA2A, ADRA2B, ADRA2C) and is characterized by its Gi/o protein-coupled inhibition of adenylate cyclase, reducing intracellular cAMP levels.
ADRA2B has the typical seven-transmembrane GPCR structure:
¶ Transmembrane Domain
- Seven α-helices: Canonical GPCR fold
- Conserved motifs: For ligand binding (asparagine in TM7)
- Orthosteric site: Binds catecholamines and imidazoles
¶ Extracellular Domain
- N-terminal tail: Short extracellular sequence
- Glycosylation sites: N-linked glycosylation
¶ Intracellular Domain
- C-terminal tail: Phosphorylation sites for desensitization
- G protein coupling domain: Gi/o protein specificity
ADRA2B couples to Gi/o proteins:
- Agonist binding (norepinephrine, clonidine)
- Gi/o protein activation
- Inhibition of adenylate cyclase
- Reduced cAMP production
- Activation of GIRK channels (hyperpolarization)
- Sympathetic inhibition: Reduced norepinephrine release
- Blood pressure regulation: Central and peripheral effects
- Analgesia: Spinal cord pain modulation
- Sedation: CNS depressant effects
- Thermoregulation: Body temperature control
ADRA2B is expressed in:
- CNS: Brainstem, spinal cord, cortex, hippocampus
- Peripheral: Platelets, adipocytes, pancreas
- Gi/o coupling: Inhibits adenylate cyclase
- Reduced cAMP: Decreased PKA activity
- Beta-gamma subunits: K+ channel activation
- Hyperpolarization: K+ efflux via GIRK channels
- Reduced neuronal firing: Decreased excitability
- Presynaptic inhibition: Reduced neurotransmitter release
- Clonidine: Alpha-2 agonist, antihypertensive
- Guanfacine: Alpha-2 agonist, ADHD treatment
- Yohimbine: Alpha-2 antagonist, cognitive effects
- Neuroprotection: Alpha-2 agonism is protective
- Memory function: Alpha-2 in prefrontal cortex
- Analgesia: Alpha-2 in pain pathways
- Locus coeruleus: High expression in LC neurons
- Prefrontal cortex: Layer-specific expression
- Spinal cord: Dorsal horn neurons
- Sympathetic nerve terminals: Presynaptic autoreceptor
- Adrenal medulla: Catecholamine regulation
- Adra2b knockout: Cardiovascular phenotypes
- Transgenic overexpression: Behavioral effects
- Receptor occupancy: PET ligands for alpha-2
- Functional imaging: Receptor activation studies
- Noradrenergic dysfunction: ADRA2B in attention and cognition
- Amyloid effects: α2-adrenergic modulation of Aβ responses
- Therapeutic potential: ADRA2B agonists for cognitive enhancement
- Autonomic dysfunction: Orthostatic hypotension
- L-DOPA response: ADRA2B in dyskinesias
- Evidence: Altered α2-adrenergic signaling in PD
- Neuroprotection: α2-adrenergic in ischemic tolerance
- Blood pressure: Post-stroke hypertension management
| Drug Class |
Example |
Clinical Use |
| Agonists |
Clonidine, guanfacine |
Hypertension, ADHD |
| Antagonists |
Atipamezole |
Veterinary reversal |
| Selective agonists |
Brimonidine |
Glaucoma |
- Hypertension: Clonidine, guanfacine
- ADHD: Guanfacine (Intuniv)
- Opioid withdrawal: Clonidine
- Glaucoma: Brimonidine
The study of Adra2B Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.